StockNews.com initiated coverage on shares of ARCA biopharma (NASDAQ:ABIO – Free Report) in a research report sent to investors on Thursday. The brokerage issued a sell rating on the biopharmaceutical company’s stock.
ARCA biopharma Stock Performance
ARCA biopharma stock opened at $1.65 on Thursday. ARCA biopharma has a 1 year low of $1.56 and a 1 year high of $2.27. The company’s 50 day simple moving average is $1.69 and its 200-day simple moving average is $1.88. The company has a market capitalization of $23.93 million, a price-to-earnings ratio of -4.46 and a beta of 1.17.
Institutional Investors Weigh In On ARCA biopharma
Several large investors have recently added to or reduced their stakes in the business. HRT Financial LP acquired a new position in ARCA biopharma during the 1st quarter worth approximately $28,000. Jane Street Group LLC acquired a new position in shares of ARCA biopharma in the 4th quarter valued at $35,000. Charles Schwab Investment Management Inc. acquired a new position in shares of ARCA biopharma in the 1st quarter valued at $30,000. Virtu Financial LLC acquired a new position in shares of ARCA biopharma in the 1st quarter valued at $55,000. Finally, abrdn plc acquired a new position in shares of ARCA biopharma in the 4th quarter valued at $55,000.
About ARCA biopharma
ARCA biopharma, Inc, a clinical development stage biopharmaceutical company, engages in the development and commercialization of genetically targeted therapies for cardiovascular diseases. Its lead product candidate is Gencaro, a pharmacogenetically-targeted beta-adrenergic receptor antagonist that has completed Phase IIb trial for the treatment of atrial fibrillation in patients with chronic heart failure.
- Five stocks we like better than ARCA biopharma
- How to Invest in Insurance Companies: A Guide
- The 5 best small cap AI companies to buy now
- What Is Dividend Yield and How Do You Calculate It?
- Cirrus Logic: A chip stock you’re going to hear a lot more about
- 3 Best Fintech Stocks for a Portfolio Boost
- Archer Aviation’s sky-high progress and short interest
Receive News & Ratings for ARCA biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ARCA biopharma and related companies with MarketBeat.com's FREE daily email newsletter.